⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3763074 | 0.82 | NPC1 (0.36) | — | |
| SCHEMBL1934253 | 0.80 | CA12 (0.40) | — | |
| SCHEMBL2480663 | 0.78 | — | — | |
| SCHEMBL21815374 | 0.77 | NOS3 (0.38) | — | |
| SCHEMBL28903229 | 0.77 | NOS3 (0.38) | — | |
| SCHEMBL1934062 | 0.76 | ALDH1A1 (0.43) | — | |
| SCHEMBL8376071 | 0.74 | EPHX2 (0.40) | — | |
| SCHEMBL30957285 | 0.74 | EPHX2 (0.40) | — | |
| SCHEMBL15103300 | 0.74 | EPHX2 (0.40) | — | |
| Captamine SCHEMBL4576750 | 0.74 | TDP1 (0.65) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11981694-B2 | Acyclic thiol prodrugs | Lilac Therapeutics, Inc. (US) | 2024-05-14 | — | — | US | disclosed |
| US-11932665-B2 | Cyclic thiol prodrugs | Lilac Therapeutics, Inc. (US) | 2024-03-19 | — | — | US | disclosed |
| US-20230234979-A1 | Cyclic Thiol Prodrugs | HARP BIO INC. | 2023-07-27 | — | — | US | disclosed |
| US-20230212200-A1 | Acyclic Thiol Prodrugs | HARP BIO INC. | 2023-07-06 | — | — | US | disclosed |
| WO-2023129576-A2 | ACYCLIC THIOL PRODRUGS | Lilac Therapeutics, Inc. (US) | 2023-07-06 | — | — | WO | disclosed |
| WO-2023129577-A1 | CYCLIC THIOL PRODRUGS | Lilac Therapeutics, Inc. (US) | 2023-07-06 | — | — | WO | disclosed |
| US-20230079407-A1 | ANTI-MSR1 ANTIBODIES AND METHODS OF USE THEREOF | REGENERON PHARMACEUTICALS, INC. | 2023-03-16 | — | — | US | disclosed |
| US-11377502-B2 | Anti-MSR1 antibodies and methods of use thereof | REGENERON PHARMACEUTICALS, INC. (US) | 2022-07-05 | — | — | US | disclosed |
| EP-3790899-A1 | ANTI-MSR1 ANTIBODIES AND METHODS OF USE THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2021-03-17 | — | — | EP | disclosed |
| EP-3737420-A2 | STEROIDS AND ANTIBODY-CONJUGATES THEREOF | Regeneron Pharmaceuticals, Inc. (US) | 2020-11-18 | — | — | EP | disclosed |
| WO-2019217591-A1 | ANTI-MSR1 ANTIBODIES AND METHODS OF USE THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2019-11-14 | — | — | WO | disclosed |
| US-20190209702-A1 | STEROIDS AND ANTIBODY-CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. | 2019-07-11 | — | — | US | disclosed |
| WO-2019136487-A2 | STEROIDS AND ANTIBODY-CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2019-07-11 | — | — | WO | disclosed |